Damora Therapeutics (DMRA) Capital Expenditures Growth (3y) (2024 - 2025)
Damora Therapeutics (DMRA) Capital Expenditures Growth (3y) (2024 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | - |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn | 16.27% |
| 10 | Damora Therapeutics | 1.00 Bn | 798.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -116.91% |
| Sep 30, 2025 | 28.82% |
| Jun 30, 2025 | 120.04% |
| Mar 31, 2025 | 52.00% |
| Dec 31, 2024 | -362.92% |
| Sep 30, 2024 | 29.73% |
| Jun 30, 2024 | -29.23% |
| Mar 31, 2024 | 107.65% |